Target intelligence / Profile preview

Levamisole-sensitive nicotinic acetylcholine receptor (L-nAChR) (L-nAChR)

Target
L-nAChR
Molecular classification
Ion channel, Ligand-gated ion channel, Nicotinic acetylcholine receptor, Cys-loop receptor family
01

Overview

The Levamisole-sensitive nicotinic acetylcholine receptor (L-nAChR), also known as the L-type nicotinic receptor, is a pentameric ligand-gated ion channel primarily found in the neuromuscular junctions of nematodes, such as Caenorhabditis elegans and various parasitic helminths. It is composed of specific subunits, including UNC-38, UNC-29, and UNC-63, which distinguish it from the nicotine-sensitive (N-type) receptors and vertebrate muscle-type receptors. This receptor is the primary molecular target for the anthelmintic drug levamisole and related compounds like pyrantel and morantel. These drugs act as potent agonists, causing persistent opening of the ion channel, which leads to massive depolarization of the muscle cells and subsequent spastic paralysis of the parasite. Because the L-type subunit composition is unique to nematodes and absent in vertebrate hosts, these drugs exhibit high selective toxicity, making them effective for treating parasitic infections. However, the widespread use of these drugs has led to the emergence of resistance, often arising from genetic mutations that alter receptor composition or function. While the term "L-type" is more commonly associated with voltage-gated calcium channels in vertebrates, in the context of nicotinic receptors, it specifically refers to this levamisole-sensitive subtype in nematodes.

Other names
Nicotinic acetylcholine receptor, L-typeLevamisole receptorL-type nAChRUNC-38/UNC-29/UNC-63/LEV-1/LEV-8 complex
02

Mechanism of action

Agonist-induced persistent depolarization of the nematode muscle cell membrane, leading to spastic paralysis and expulsion of the parasite.

03

Biological functions

Neuromuscular transmissionMuscle contractionIon transportLocomotion
04

Disease associations

InfectionHelminthiasisAscariasisHookworm infectionTrichuriasis
05

Safety considerations

Anthelmintic resistanceCholinergic toxicity in host at high dosesSpecies-specific sensitivity
06

Interacting drugs

Levamisole

4 more in the full profile.

07

Biomarkers

Fecal egg count reduction (FECR)Larval development assay (LDA)Larval migration inhibition assay (LMIA)

Beyond the preview

Go deeper on Levamisole-sensitive nicotinic acetylcholine receptor (L-nAChR) (L-nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Levamisole-sensitive nicotinic acetylcholine receptor (L-nAChR) (L-nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call